Drug details
Bynfezia Pen (octreotide acetate injection, for subcutaneous use)
type of Antidiarrheals, Somatostatin Analogs
Bynfezia Pen (octreotide acetate) is a somatostatin analogue indicated for reduction of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) [somatomedin C] in adult patients with acromegaly who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses; treatment of severe diarrhea/flushing episodes associated with metastatic carcinoid tumors in adult patients; and treatment of profuse watery diarrhea associated with vasoactive intestinal peptide tumors (VIPomas) in adult patients.
This drug may have the following side effects:
- nausea,
- vomiting,
- diarrhea,
- constipation,
- abdominal discomfort,
- headache, and
- slow heart rate,
- irregular heartbeats,
- dizziness
- gas (flatulence),
- abdominal distention,
- loose stools,
- gallstones and gallbladder problems,
- abnormal stools,
- high or low blood guar (hyperglycemia or hypoglycemia),
- hypothyroidism,
- pain on injection,
The following drugs are related to Bynfezia Pen, either as a replacement or used together:
- Parlodel (bromocriptine mesylate)
- Somatuline Depot (lanreotide)
- Mycapssa (octreotide oral capsules)
- Sandostatin (octreotide acetate)
- Sandostatin LAR (octreotide acetate injection)
- Signifor (pasireotide diaspartate for injection)
- Signifor-LAR (pasireotide for injectable suspension, for intramuscular use)